Appeals Court Rejects False Claims Approach To FDA Off-Label Cases
Executive Summary
A ruling from the First Circuit suggests that plaintiffs can’t prove manufacturers violated the False Claims Act by suggesting FDA submissions were fraudulent, if FDA itself hasn’t taken any action against the manufacturer.
You may also be interested in...
Medtronic Biz Pleads Guilty In Off-Label Marketing Case
A Medtronic subsidiary has agreed to plead guilty for off-label marketing activities that occurred prior to Medtronic's acquisition. Overall, the firm says it has settled three investigations with a total pay-out of $50.9m. US FDA is underscoring the case as an example of the agency pursuing companies that "put profit over safety."
Unlocking Legalities: Ninth Circuit Allows Wider Range Of False Claim Suits
The Ninth Circuit Court of Appeals allowed False Claims Act allegations against drug manufacturers Gilead Sciences to move forward despite a US Supreme Court ruling last year that raised FCA standards.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.